Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Sells $5,763,494.90 in Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) EVP Robert Desantis sold 11,545 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $499.22, for a total value of $5,763,494.90. Following the completion of the transaction, the executive vice president now owns 5,224 shares of the company’s stock, valued at approximately $2,607,925.28. This represents a 68.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG opened at $484.44 on Friday. Intuitive Surgical, Inc. has a 52 week low of $364.17 and a 52 week high of $616.00. The stock’s fifty day moving average is $567.46 and its 200 day moving average is $531.60. The stock has a market capitalization of $172.55 billion, a P/E ratio of 75.58, a PEG ratio of 5.85 and a beta of 1.43.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Morgan Stanley raised shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $522.00 to $650.00 in a research report on Monday, December 2nd. Citigroup lifted their price target on Intuitive Surgical from $640.00 to $711.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Stifel Nicolaus upped their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Truist Financial lifted their target price on Intuitive Surgical from $640.00 to $666.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. Finally, Royal Bank of Canada raised their price target on Intuitive Surgical from $611.00 to $641.00 in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Hedge Funds Weigh In On Intuitive Surgical

Hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank acquired a new position in Intuitive Surgical during the fourth quarter valued at approximately $2,401,493,000. Massachusetts Financial Services Co. MA acquired a new stake in Intuitive Surgical in the third quarter valued at about $558,807,000. Proficio Capital Partners LLC raised its stake in Intuitive Surgical by 89,098.8% during the fourth quarter. Proficio Capital Partners LLC now owns 949,967 shares of the medical equipment provider’s stock worth $495,845,000 after acquiring an additional 948,902 shares in the last quarter. FMR LLC boosted its stake in shares of Intuitive Surgical by 8.3% in the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock valued at $5,389,765,000 after purchasing an additional 838,793 shares in the last quarter. Finally, Capital Research Global Investors grew its holdings in shares of Intuitive Surgical by 25.5% during the 4th quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider’s stock valued at $1,764,904,000 after purchasing an additional 687,906 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.